Bunchoo Pongtanakul

Bunchoo Pongtanakul

Auto-generated profile, based on publicly available information

Bunchoo Pongtanakul

Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2022 in Transfusion
Verified
Journal Article
Closed access
NTNattiya Teawtrakul
Nattiya Teawtrakul
DSDuantida Songdej
Duantida Songdej
CHChattree Hantaweepant
Chattree Hantaweepant
ATAdisak Tantiworawit
Adisak Tantiworawit
SLSupanun Lauhasurayotin
Supanun Lauhasurayotin
RGRed Blood Cell Disorders Study Group
Red Blood Cell Disorders Study Group

24 July 2020 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
BPBunchoo Pongtanakul
Bunchoo Pongtanakul
NSNongnuch Sirachainan
Nongnuch Sirachainan
PSPacharapan Surapolchai
Pacharapan Surapolchai
PCPimlak Charoenkwan
Pimlak Charoenkwan
WCWorawut Choeyprasert
Worawut Choeyprasert
SHSuradej Hongeng
Suradej Hongeng

30 October 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
DSDuantida Songdej
Duantida Songdej
NTNattiya Teawtrakul
Nattiya Teawtrakul
NLNapat Laoaroon
Napat Laoaroon
PKPatcharee Komvilaisak
Patcharee Komvilaisak
PSPornpun Sripornsawan
Pornpun Sripornsawan
RGRed Blood Cell Disorders Study Group
Red Blood Cell Disorders Study Group

24 July 2025 in Blood Advances
Verified
Journal Article
Open access
ASAkiko Shimamura
Akiko Shimamura
AMAlexey Maschan
Alexey Maschan
CBCarolyn Bennett
Carolyn Bennett
SSSujith Samarasinghe
Sujith Samarasinghe
JFJason E Farrar
Jason E Farrar
DWDavid A. Williams
David A. Williams
Severe aplastic anemia (SAA) is a rare, life-threatening disease with acquired pancytopenia and hypocellular bone marrow. ESCALATE evaluated eltrombopag in combination with immunosuppressive therapy (IST) in pediatric patients (aged 1 to <18 years) with relapsed/refractory (R/R) or treatment-naïve SAA. The eltrombopag starting dose was 25 mg/d for patients aged 1 to <6 years and 50 mg/d for patients aged 6 to <18 years; dose modifications (maximum dose, 150 mg/d) were allowed to achieve a target platelet count of 50 × 109/L to 200 × 109/L. Eltrombopag was administered with cyclosporine A, with or without horse antithymocyte globulin, for 26 weeks and could be extended if clinically beneficial. Fifty-one patients were treated (R/R SAA, n = 14; treatment-naïve SAA, n = 37). Data were analyzed overall and as 2 cohorts: R/R and treatment-naïve cohorts. The overall response rate (ORR; per North American Pediatric Aplastic Anemia Consortium criteria) at 26 weeks was 54.9% in both cohorts combined and 71.4% and 48.6% in the R/R and treatment-naïve cohorts, respectively; most responders had sustained responses after discontinuing eltrombopag. Among baseline transfusion-dependent patients, 66.7% and 76.7% achieved red blood cell and platelet transfusion independence, respectively, with rates of 70% and 80% for the R/R cohort and 65.6% and 75.8% for the treatment-naïve cohort, respectively. The most common treatment-related adverse events were abnormalities in liver function tests, including increased bilirubin (43.1%), alanine aminotransferase (37.3%), and aspartate aminotransferase (33.3%). Eltrombopag with IST showed a trend toward a favorable ORR in the R/R cohort, with no new safety signals. This trial was registered at www.clinicaltrials.gov as #NCT03025698.

10 May 2023 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
CMChatphatai Moonla
Chatphatai Moonla
DSDarintr Sosothikul
Darintr Sosothikul
BPBunchoo Pongtanakul
Bunchoo Pongtanakul
BSBundarika Suwanawiboon
Bundarika Suwanawiboon
CTChanchai Traivaree
Chanchai Traivaree
PAPantep Angchaisuksiri
Pantep Angchaisuksiri
Hemophilia is an inherited bleeding disorder caused by deficiency of a specific coagulation factor. Factor VIII deficiency is responsible for hemophilia A while factor IX deficiency is responsible for hemophilia B. As per the 2020 annual global survey by the World Federation of Hemophilia, only 1828 Thai hemophiliacs have been registered to the national healthcare system. The reason for the low number is the underdiagnosis which is a major concern in the real-world practice among Asian countries. In Thailand, most hemophiliacs are diagnosed by general practitioners, pediatricians or internists at rural hospitals and are referred to hemophilia specialists at the Hemophilia Treatment Centers (HTCs). Despite the challenges pertaining to infrastructure and cost of treatment, Thailand has progressed substantially in providing the required hemophilia care, as evidenced by an evolution in acquiring and sharing knowledge as well as collaborative efforts among multiple stakeholders over the past three decades. In this letter-to-the-editor, the authors have summarized the practices for and challenges faced with hemophilia management in Thailand.

22 June 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
KSKleebsabai Sanpakit
Kleebsabai Sanpakit
NNNattee Narkbunnam
Nattee Narkbunnam
JBJassada Buaboonnam
Jassada Buaboonnam
CTChayamon Takpradit
Chayamon Takpradit
VVVip Viprakasit
Vip Viprakasit
BPBunchoo Pongtanakul
Bunchoo Pongtanakul